2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2356

Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Abstract Number: 409

Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment
Abstract Number: 1950

Apolipoprotein L1 Variant-Carrying Monocytes Exhibit Mitochondrial Respiration Defects
Abstract Number: 2230

Applicability of FRAX in Clinical Practice: 10-year Results
Abstract Number: 2865

Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
Abstract Number: 765

Application of Different Sets of Classification/diagnostic Criteria for Polymyalgia Rheumatica: Single Center Study of 100 Patients
Abstract Number: 784

Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Abstract Number: 799

Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital
Abstract Number: 1191

Application of the Systemic Lupus Erythematosus (SLE) Quality Indicators in Patients Attending a Young Adult Transition Program
Abstract Number: 654

Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease
Abstract Number: 1695

Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases
Abstract Number: 1012

Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Abstract Number: 1224

AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
Abstract Number: 1229

AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
Abstract Number: 744

Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].